Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

Nautilus Biotechnology Q2 EPS $(0.14) Beats $(0.16) Estimate

Author: Benzinga Newsdesk | July 30, 2024 06:09am
Nautilus Biotechnology (NASDAQ:NAUT) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(0.16) by 12.5 percent. This is a 7.69 percent decrease over losses of $(0.13) per share from the same period last year.

Posted In: NAUT

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist